Use: Labeled indications
- 1.
Full indications and usage US FDA label
1. INDICATIONS & USAGE Calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). Calcium acetate capsules are a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. (1)
Contraindications
4. CONTRAINDICATIONS Patients with hypercalcemia. Hypercalcemia. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2. DOSAGE & ADMINISTRATION The recommended initial dose of calcium acetate capsules for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 capsules with each meal. Starting dose is 2 capsules with each meal. (2) Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 capsules with each meal. (2)
Dosing: Altered kidney function
2. DOSAGE & ADMINISTRATION The recommended initial dose of calcium acetate capsules for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 capsules with each meal. Starting dose is 2 capsules with each meal. ( 2 ) Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 capsules with each meal. ( 2 )
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 GERIATRIC USE Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Calcium carbonate): 200 mg Film-Coated Tablet (equivalent to 500 mg, 200 mg Tablet (equivalent to 500 mg, 500 mg Tablet (equivalent to 1,250 mg, 500 mg Tablet (equivalent to 1.25 g
- Calcium carbonate) tablet: 200 mg Calcium (equivalent to 500 mg, 500 mg (equivalent to 1.25 g
- Tablet: 500 mg
- Calcium carbonate) chewable tablet: 500 mg (equivalent to 1,250 mg
- Calcium lactate): 119.38 mg Tablet (equivalent to 650 mg
- Calcium lactate) tablet: 60 mg (equivalent to 325 mg
- Calcium-glucono-galacto-gluconate) solution for injection: 100 mg/mL (10 % w/v) Equivalent to 137.50 mg
- Elemental calcium) tablet: 125 g (equivalent to 500 mg
Registered products in the Philippines
19 products registered with the Food and Drug Administration (FDA) Philippines list Calcium as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products19
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AdcalCalcium (as carbonate) | 500 mg Tablet (equivalent to 1.25 g Calcium carbonate)Alu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | Rx | Kanion Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-9943 | Jun 29, 2031 | |
AmbicalCalcium | 500 mg (equivalent to 1.25 g Calcium Carbonate) TabletAlu-PVC/PVDC Blister Pack x 10's (Box 30's and 100's) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-9140 | Sep 14, 2031 | |
CalbornateCalcium (as Carbonate) | 125 g (equivalent to 500 mg elemental Calcium) TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-13824 | Apr 27, 2028 | |
CalbornateCalcium (as Carbonate) | 500 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-13820 | Apr 27, 2028 | |
CalcieCalcium | 500 mg Tablet (Equivalent to 1,250 mg Calcium Carbonate)Alu/PVDC/PVC Blister Pack x 10's (Box of 100's) | OTC | Medicamen Biotech Ltd.India | MedEthix, Inc. | DRP-9132 | Sep 10, 2028 | |
CalcilifeCalcium | 500 mg Tablet (equivalent to 1.25 g Calcium Carbonate)Alu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | OTC | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-9140-01 | Jul 20, 2031 | |
CalmateCalcium (as Carbonate) | 200 mg Film-Coated Tablet (equivalent to 500 mg Calcium Carbonate)Alu/Clear PVC/PVdC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY46448 | Nov 6, 2028 | |
CalsateCalcium (as Calcium Carbonate) | 500 mg (equivalent to 1.25 g Calcium Carbonate) TabletAlu/PVC Blister Pack x 10's (Box of 50's) | OTC | Millimed Company LimitedThailand | Endure Medical, Inc. | DR-XY46582 | May 27, 2029 | |
MarbonateCalcium (as Carbonate) | 500 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-13820-01 | Apr 27, 2028 | |
NoneCalcium (as gluconate) | 100 mg/ml (10% w/v) Equivalent to 137.50 mg Calcium-Glucono-Galacto-Gluconate) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 10 mL (Box of 5's) | Rx | Harson LaboratoriesIndia | Phil Pharmawealth Inc. | DR-XY25316 | Jun 14, 2029 | |
NoneCalcium (as Lactate) | 119.38 mg Tablet (equivalent to 650 mg Calcium Lactate)120 mL Amber Glass Bottle with Metal Screw Cap (Box of 100's) | OTC | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-8124 | Mar 21, 2029 | |
NoneCalcium (as Carbonate) | 200 mg Calcium (equivalent to 500 mg Calcium Carbonate) TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker's Laboratories, Inc.Philippines | TGP PHARMA, INC. | DRP-5199-01 | Mar 3, 2028 | |
NoneCalcium (as Carbonate) | 200 mg Tablet (equivalent to 500 mg Calcium Carbonate)Alu/ PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5199 | Mar 3, 2028 | |
NoneCalcium (as Carbonate) | 200 mg Tablet (equivalent to 500 mg Calcium Carbonate)Alu/PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker's Laboratories, Inc.Philippines | Drugmaker's Laboratories, Inc. | DRP-5199-03 | Mar 3, 2028 | |
NoneCalcium (as carbonate). | 500 mg (equivalent to 1,250 mg Calcium Carbonate) Chewable TabletAlu/PVC Blister Pack x 10 (Box of 100's) | Rx | Celogen Generics Pvt. Ltd.India | Khriz Pharma Trading, Inc. | DRP-11685 | May 27, 2027 | |
NoneCalcium | 500 mg Tablet (equivalent to 1,250 mg Calcium Carbonate)Alu/PVDC/PVC Blister Pack x 10's (Box of 100's) | OTC | Medicamen Biotech LimitedIndia | Uniqure Pharma Inc. | DRP-9120 | Sep 4, 2028 | |
NoneCalcium (as carbonate) | 500 mg Tablet (equivalent to 1.25 g Calcium carbonate)Alu Strip Foil x 4’s (Box of 100’s) | OTC | Hizon Laboratories, Inc.Philippines | — | DR-XY41647 | Feb 5, 2028 | |
UnbrandedCalcium | 60 mg (equivalent to 325mg Calcium Lactate) TabletAmber Glass Bottle x 100's Box of 1's | OTC | Amherst Laboratories, Inc.Laguna | Trader: RiteMED Phils., Inc. | DRP-9655 | Apr 22, 2031 | |
(no brand name)Calcium | 500 mg TabletAlu/Dark Maroon Colored PVC Blister pack of 10's (Box of 30's) | OTC | Factors Group of Nutritional Companies Inc.Canada | Watsons Personal Care Stores (Philippines), Inc.Importer: Naturehealth, Inc. | DRP-15899 | Sep 26, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3. DOSAGE FORMS & STRENGTHS Capsule: 667 mg calcium acetate, USP per capsule. Capsule: 667 mg calcium acetate (3)
Warnings/Precautions
- 5. WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting calcium acetate capsules and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate capsules. (5.1)
- Hypercalcemia may aggravate digitalis toxicity. (5.2)
5.1 Hypercalcemia
5.1 Hypercalcemia Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (calcium acetate capsules). Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with calcium acetate capsules. An overdose of calcium acetate capsules may lead to progressive hypercalcemia, which may require emergency measures.
Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate capsules dosage or discontinue the treatment, depending on the severity of hypercalcemia. More severe hypercalcemia (Ca>12 mg/dL) is associated with confusion, delirium, stupor and coma.
Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate capsules therapy. Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate capsules dose or temporarily discontinuing therapy.
Decreasing or discontinuing Vitamin D therapy is recommended as well. Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of calcium acetate capsules on the progression of vascular or soft tissue calcification has not been determined.
Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. Maintain the serum calcium-phosphorus (Ca × P) product below 55 mg2/dL2.
5.2 Concomitant Use with Medications
5.2 Concomitant Use with Medications Hypercalcemia may aggravate digitalis toxicity.
Drug interactions
Drug interactions (US label) US FDA label
7. DRUG INTERACTIONS The drug interaction of calcium acetate capsules is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl and hydroxyl groups). Calcium acetate capsules may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. There are no empirical data on avoiding drug interactions between calcium acetate or calcium acetate capsules and most concomitant drugs.
When administering an oral medication with calcium acetate capsules where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate capsules or calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range.
Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate. Calcium acetate capsules may decrease the bioavailability of tetracyclines or fluoroquinolones. (7) When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate capsules, or consider monitorinG blood levels of the drug.
(7) 7.1 Ciprofloxacin In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets approximately 2.7 g decreased the bioavailability of ciprofloxacin by approximately 50%.
Adverse reactions
- 6. ADVERSE REACTIONS Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1)] The most common (> 10%) adverse reactions are hypercalcemia, nausea, and vomiting. (6.1)
- In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. (6) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies, calcium acetate has been generally well tolerated.
Calcium acetate capsules were studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebo-controlled, crossover study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1. Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis Preferred Term Total adverse reactions reported for calcium acetate n=167 (n%) 3-mo, open-label study of calcium acetate n=98 (n%) Double blind, placebo-controlled, cross-over study of calcium acetate n=69 Calcium acetate (n%) Placebo (n%) Nausea 6 (3.6) 6 (6.1) 0 (0.0) 0 (0.0) Vomiting 4 (2.4) 4 (4.1) 0 (0.0) 0 (0.0) Hypercalcemia 21 (12.6) 16 (16.3) 5 (7.2) 0 (0.0) Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting.
More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate capsules induced hypercalcemia. Isolated cases of pruritus have been reported, which may represent allergic reactions.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.
To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adverse reaction frequency tables (US label) US FDA label
| Preferred Term | Total adverse reactions reported for calcium acetate n=167 (n%) | 3-mo, open-label study of calcium acetate n=98 (n%) | Double blind, placebo-controlled, cross-over study of calcium acetate n=69 | |
|---|---|---|---|---|
| Calcium acetate (n%) | Placebo (n%) | |||
| Nausea | 6 (3.6) | 6 (6.1) | 0 (0.0) | 0 (0.0) |
| Vomiting | 4 (2.4) | 4 (4.1) | 0 (0.0) | 0 (0.0) |
| Hypercalcemia | 21 (12.6) | 16 (16.3) | 5 (7.2) | 0 (0.0) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 PREGNANCY Pregnancy Category C Calcium acetate capsules contain calcium acetate. Animal reproduction studies have not been conducted with calcium acetate capsules, and there are no adequate and well controlled studies of calcium acetate capsules use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1)].
Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate capsules treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 NURSING MOTHERS Calcium acetate capsules contain calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate capsules is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.
Mechanism of action
12.1 MECHANISM OF ACTION Calcium acetate (calcium acetate capsules) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 PHARMACODYNAMICS Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.
Pharmacokinetics
Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD. 12.1 MECHANISM OF ACTION Calcium acetate (calcium acetate capsules) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. 12.2 PHARMACODYNAMICS Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions.
Pharmacokinetics (US label) US FDA label
12. CLINICAL PHARMACOLOGY Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD. 12.1 MECHANISM OF ACTION Calcium acetate (calcium acetate capsules) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. 12.2 PHARMACODYNAMICS Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions.
This range represents data from both healthy subjects and renal dialysis patients under various conditions.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Calcium |
| PNF listing | Oral: tablet (equiv. to 500 mg elemental calcium) (as lactate) tablet/chewable tablet (equiv. to 500 mg and 600 mg elemental calcium) (as carbonate) powder, USP grade (as chloride) |
| PNF listing | Inj.: 10% solution in 10 mL ampul (IV) (as gluconate) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Calcium Acetate · AvPAK [US FDA-approved label, version 1, May 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52e35dd6-db95-98e6-e063-6294a90ab801
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .